GlaxoSmithKline (LON:GSK) had its price target reduced by Morgan Stanley from GBX 1,450 ($19.42) to GBX 1,400 ($18.75) in a report published on Friday. They currently have an underweight rating on the stock.

A number of other equities analysts have also recently commented on GSK. Deutsche Bank dropped their price objective on shares of GlaxoSmithKline from GBX 1,720 ($23.03) to GBX 1,610 ($21.56) and set a hold rating for the company in a research note on Monday, August 7th. Goldman Sachs Group set a GBX 1,900 ($25.45) price objective on shares of GlaxoSmithKline and gave the stock a buy rating in a research note on Tuesday, August 8th. Berenberg Bank dropped their price objective on shares of GlaxoSmithKline from GBX 1,885 ($25.24) to GBX 1,835 ($24.57) and set a buy rating for the company in a research note on Wednesday, August 9th. Jefferies Group dropped their price objective on shares of GlaxoSmithKline from GBX 1,900 ($25.45) to GBX 1,750 ($23.44) and set a buy rating for the company in a research note on Thursday, August 24th. Finally, Liberum Capital reissued a buy rating and issued a GBX 1,900 ($25.45) price objective on shares of GlaxoSmithKline in a research note on Wednesday, August 30th. Three analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have given a buy rating to the stock. GlaxoSmithKline currently has a consensus rating of Hold and an average price target of GBX 1,581.90 ($21.19).

Shares of GlaxoSmithKline (LON GSK) traded up GBX 10.50 ($0.14) during trading hours on Friday, hitting GBX 1,290 ($17.28). 12,985,549 shares of the company’s stock were exchanged, compared to its average volume of 11,220,000. GlaxoSmithKline has a 1-year low of GBX 1,291.50 ($17.30) and a 1-year high of GBX 1,724.50 ($23.09).

GlaxoSmithKline (LON:GSK) last issued its quarterly earnings data on Wednesday, October 25th. The company reported GBX 32.50 ($0.44) EPS for the quarter, topping analysts’ consensus estimates of GBX 31.80 ($0.43) by GBX 0.70 ($0.01). GlaxoSmithKline had a net margin of 17.79% and a return on equity of 461.88%. The business had revenue of GBX 784.30 billion during the quarter.

The business also recently disclosed a dividend, which will be paid on Thursday, January 11th. Investors of record on Thursday, November 9th will be issued a dividend of GBX 19 ($0.25) per share. The ex-dividend date of this dividend is Thursday, November 9th. This represents a yield of 1.41%.

In other GlaxoSmithKline news, insider Simon Dingemans purchased 1,076 shares of GlaxoSmithKline stock in a transaction dated Thursday, October 12th. The stock was acquired at an average price of GBX 1,527 ($20.45) per share, for a total transaction of £16,430.52 ($22,004.18). Also, insider Urs Rohner purchased 473 shares of GlaxoSmithKline stock in a transaction dated Wednesday, October 25th. The stock was acquired at an average price of GBX 1,518 ($20.33) per share, with a total value of £7,180.14 ($9,615.83). Insiders have purchased a total of 1,576 shares of company stock valued at $2,400,376 in the last quarter.

COPYRIGHT VIOLATION WARNING: “GlaxoSmithKline (GSK) Given New GBX 1,400 Price Target at Morgan Stanley” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/12/02/glaxosmithkline-gsk-given-new-gbx-1400-price-target-at-morgan-stanley.html.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Stock Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related stocks with our FREE daily email newsletter.